Using readily available clinicopathologic information, a team of investigators developed a risk calculator to predict disease recurrence in patients with thin melanomas.
Cavrotolimod is a toll-like receptor 9 agonist that is designed to induce anticancer immune responses through proprietary spherical nucleic acid (SNA™) technology.
A team of researchers assessed the relationship between BRAFV600-mutant ctDNA in plasma samples and outcomes in patients with BRAFV600 mutation-positive melanoma.
The differences in incidence, clinical features, genetics, treatment and outcome, in cutaneous melanoma in White vs people of African descent populations is reviewed.
The FDA has approved Libtayo for the treatment of patients with locally advanced and metastatic basal cell carcinoma (laBCC) who have previously received a hedgehog pathway inhibitor (HHI) or for whom an HHI is not appropriate
Patients may neglect their skin health when the weather gets cold, but they remain at risk of damaging their skin and developing cancer in the winter, too. What winter-specific risk factors can clinicians discuss with patients?
Investigators assessed and synthesized existing data on the association of UV exposure and the risk for cutaneous melanoma in individuals with skin of color.
Investigators compared recurrence-free survival and overall survival outcomes in patients randomly assigned to receive neoadjuvant talimogene laherparepvec (T-VEC) followed by immediate surgery or surgery alone.
“‘Trended strongly’ is code for ‘we failed to meet statistical significance,’” remarked one expert, when she was asked to scrutinize the conclusions of a recent post hoc analysis.
Pretreatment with G-CSF prior to receiving an autologous DC-based vaccine resulted in worse outcomes compared with no G-CSF, according to results of a phase 2b study.
Despite relying on glycolysis, there is growing evidence that many tumor types still have high levels of mitochondrial energy metabolism and functioning oxidative phosphorylation. One such subset of tumors is melanoma, potentially playing a role in both tumor progression and resistance to therapy. This has led researchers to wonder whether targeting mitochondrial respiration could be…
BEMPEG combined with nivolumab resulted in deep and durable responses among patients with treatment-naive metastatic melanoma, according to phase 2 data.
More than half of patients with resected stage 3 melanoma with BRAF V600E or V600K mutations receiving a year’s worth of adjuvant dabrafenib and trametinib were still alive 5 years later.
Comorbidities can have an impact on what you as a medical professional think is the best course of treatment for your patients. Can they also affect a patient’s thinking on treatment? Comorbidities such as cardiovascular disease, hypertension, and depression can contribute to how a patient’s body responds to treatment and its attendant stress. A recent…